Kuros Biosciences AG
SIX:KURN
P/OCF
Price to OCF
Price to Operating Cash Flow (P/OCF) ratio is a valuation multiple that measures the value of a company’s market capitalization relative to the operating cash flow it generates. Some analysts prefer P/OCF over P/E since earnings can be more easily manipulated than cash flows.
Market Cap | P/OCF | ||||
---|---|---|---|---|---|
CH |
Kuros Biosciences AG
SIX:KURN
|
336.8m CHF | -37.9 | ||
US |
Abbvie Inc
NYSE:ABBV
|
295.2B USD | 13.1 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
165.2B USD | 20.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.5B USD | 31.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
110.4B USD | 23.3 | ||
AU |
CSL Ltd
ASX:CSL
|
139.9B AUD | 34.7 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
79.7B USD | 9.4 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
59.8B USD | -20.8 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -79.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
33.8B USD | 20.5 | ||
KR |
Celltrion Inc
KRX:068270
|
39.4T KRW | 93.2 |
P/OCF Forward Multiples
Forward P/OCF multiple is a version of the P/OCF ratio that uses forecasted operating cash flow for the P/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.